Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | DRD3 | P35462 | 5/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14231689 | 1.00 | KMT2A (0.44) | KMT2ADRD2DRD3MTNR1AMTNR1B | |
| SCHEMBL30049087 | 0.84 | KDM4E (0.48) | KMT2ADRD2DRD3 | |
| SCHEMBL23856566 | 0.84 | KDM4E (0.48) | KMT2ADRD2DRD3 | |
| SCHEMBL29233940 | 0.83 | KMT2A (0.44) | KMT2AF2CA1CA2F10 | |
| SCHEMBL14392825 | 0.83 | KMT2A (0.46) | KMT2AMTNR1AMTNR1BF2CA1 | |
| SCHEMBL31278113 | 0.83 | KMT2A (0.46) | KMT2AMTNR1AMTNR1BF2CA1 | |
| SCHEMBL9979464 | 0.83 | CA1 (0.46) | KMT2ADRD2DRD3CA1CA2 | |
| SCHEMBL1339793 | 0.83 | KMT2A (0.46) | KMT2AMTNR1AMTNR1BF2CA1 | |
| SCHEMBL4013407 | 0.81 | KMT2A (0.44) | KMT2AMTNR1AMTNR1BF2CA1 | |
| SCHEMBL2071684 | 0.81 | KMT2A (0.44) | KMT2AMTNR1AMTNR1BF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | KMT2A 1449/4885DRD2 801/4885DRD3 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.